Get all your news in one place.
100's of premium titles.
One app.
Start reading
Medical Daily
Medical Daily
Health
Dorothy Brooks

BIZARRE: Hibsago approval gives some hepatitis b patients a shot at functional cure reached by about 1 in 5 | Mind Blowing Facts

The Food and Drug Administration has approved Hibsago (bepirovirsen), a first-of-its-kind treatment designed to help some adults with chronic hepatitis B keep the virus under control after stopping all medication. In clinical trials, 19% of patients who received the drug still had the virus under control 24 weeks after ending all hepatitis B treatment, compared with none who received a placebo, according to the FDA's Oct. 20 announcement.

That result, often called a functional cure, means the virus's DNA and a key viral protein, hepatitis B surface antigen, can no longer be detected in the blood after treatment stops. It does not mean the virus is gone from the body.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.